| payload |
{"created_at":"2026-04-16T02:08:52.472 {"created_at":"2026-04-16T02:08:52.472606+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:61598d4f5bb004f5","evidence_event_ids":["evt_acc1f00b098a"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016854.txt","as_of":"2026-04-16T02:08:52.472606+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016854.txt","company":"Vivos Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016854.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_0db5ac0b9dd2f132","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016854.txt","content_type":"text/plain","enriched_at":"2026-04-16T02:17:17.721149+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016854.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016854.txt","source_event_id":"evt_acc1f00b098a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"10-K","fp":"420bceeeae399abc","kind":"sec_filing","published_at":"20260415","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-15","2026-04-16","June 30, 2025","April 15, 2026"],"entities":[{"asset_class":"equity","name":"Vivos Therapeutics, Inc.","relevance":"high","symbol":"VVOS","type":"issuer"}],"event_type":"listing","information_gaps":["The provided text does not include the filing\u2019s signature date, auditor information, or the actual financial statements/MD&A content.","The provided text does not specify what changed versus any prior known state (no prior filing comparison content is included).","The cover page contains a placeholder for \u201caggregate market value \u2026 was approximately $\u201d but the numeric value is missing from the provided text.","No specific guidance, financial implications, or quantified results are present in the provided excerpt."],"key_facts":["The document is an SEC filing titled \u201cFORM (Mark One)\u201d and is an Annual Report on Form 10-K (per signal headline and source summary).","The filing includes standard cover-page checkboxes regarding reporting status and electronic submission of Interactive Data Files.","The filing includes a section stating it contains \u201cforward-looking statements\u201d and identifies where they are located (Risk Factors and MD&A).","The filing states that readers are cautioned that risks and uncertainties may cause actual results to differ materially from forward-looking statements."],"numeric_claims":[{"label":"shares outstanding as of","value":"April 15, 2026 (stated on cover page)"}],"primary_claim":"Vivos Therapeutics, Inc. filed a Form 10-K with the SEC (filed 2026-04-15 per the source summary).","relevance_score":0.72,"sentiment":"neutral","source_quality":"high","summary":"Vivos Therapeutics, Inc. filed an Annual Report on Form 10-K with the SEC. The provided text includes standard 10-K cover-page disclosures and forward-looking statements language, but does not include specific financial results or business updates.","topics":["SEC filing","Form 10-K","forward-looking statements","cover page disclosures"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 10-K \u00b7 Vivos Therapeutics, Inc. \u00b7 Filed 20260415","ticker":"VVOS","tickers":["VVOS"],"title":"VVOS filed 10-K","url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016854.txt"}}... |